GBC-HpVac announces that the lead validation study of its drug candidate has successfully reached its primary endpoint against asthma.
GBC-R1 is an immuno-modulatory protein of microbiotic origin that was tested this summer at the respiratory pharmacology department of the renowned Fraunhofer ITEM in Germany. The primary endpoint of this study was the confirmation that the recombinant version of GBC-R1 retains its capacity to improve lung function in a murine model of allergic asthma in a dose-dependent manner. This study also confirms the pertinence of the award-winning academic discovery of the role of this protein against allergic diseases, including allergic asthma, atopic dermatitis and food allergies.
“We are very pleased that this validation study has confirmed the activity of GBC-R1 in improving lung function and are proud to once again deliver a project milestone on budget and on time. We look forward to pursuing the lead optimization of our validated lead” says Dr. Jeffrey Shaw, CEO.
GBC-HpVac expects that these results will be helpful in finalizing the current series A fundraising, with a first tranche of CHF 3 million and second tranche of CHF 5 million.
